Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models
8.7.2025 15:30:00 EEST | ACCESS Newswire | Press release
Expanded offering delivers integrated radiopharmaceutical studies using clinically relevant isotopes and highly characterized PDX tumor models
HACKENSACK, NJ / ACCESS Newswire / July 8, 2025 / Champions Oncology (NASDAQ:CSBR) a leading translational oncology research organization, today announced the full commercial launch of its radiopharmaceutical services platform. This milestone follows the expansion of the company's radioactive materials license, the completion of the radiochemistry infrastructure, and the successful screening of more than thirty PDX models in collaboration with pharmaceutical and biotech partners.
Champions now offers fully integrated radiopharmaceutical workflows combining in vitro, ex-vivo biodistribution, and therapeutic efficacy studies across a wide range of isotopes. The company's platform is uniquely differentiated by its extensive bank of patient-derived xenograft (PDX) tumor models, enabling drug developers to evaluate radiolabeled agents in clinically relevant systems.
"Radiopharmaceuticals represent one of the most exciting frontiers in precision oncology," said Mike Ritchie, Chief Commercial Officer at Champions Oncology. "By combining advanced radiochemistry infrastructure with the world's most deeply characterized PDX bank, we're helping our clients generate meaningful, translational data that drives confident decision-making earlier in oncology drug development."
Champions updated radioactive materials license now includes support for ten key isotopes: Lu-177, Ac-225, In-111, Cu-67, Y-90, Pb-212, At-211 Tb-161, Cu-64, and Zr-89. These additions enable a wide range of study designs including radioligand therapy (RLT), antibody radionuclide conjugates (ARCs), and theranostic approaches.
"Our goal is to help biopharma partners answer critical questions faster, with data that reflects real tumor biology," continued Mike Ritchie, Chief Commercial Officer at Champions Oncology. "The integration of radionuclide workflows into our PDX platform provides a uniquely powerful preclinical toolset for evaluating biodistribution, tumor targeting, and therapeutic effect."
To learn more about Champions Oncology's radiopharmaceutical capabilities, visit:
https://www.championsoncology.com/radiopharmaceutical
About Champions Oncology
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Contact
Gavin Cooper
Vice President, Global Marketing
gcooper@championsoncology.com
518 488 9026
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
Champions Oncology, Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Northfield Announces Change of Corporate Name to Juno International Corporation9.6.2026 22:45:00 EEST | Press release
TORONTO, ON / ACCESS Newswire / June 9, 2026 / Northfield Capital Corporation (TSXV:NFD.A) (the "Corporation") today announced that it will change its corporate name to "Juno International Corporation" effective Thursday, June 11, 2026 (the "Name Change"). The trading symbol for the Corporation's class A restricted voting shares (the "Shares") will change to "JUN.A" following the completion of the Name Change. Trading of the Shares on the TSX Venture Exchange under the new name will commence at the open of markets on Thursday, June 11, 2026. There is no change in the capitalization of the Corporation in connection with the Name Change. No action is required by existing shareholders of the Corporation with respect to the Name Change. Outstanding certificates and Direct Registration Statement Advices with respect to the Shares do not need to be exchanged. Upon completion of the Name Change, the Company's new CUSIP number for the Shares will be 482045101 and its new ISIN number will be CA
WLF Energy and Farasis Energy Sign Strategic Partnership Agreement to Accelerate Next-Generation Energy Storage Solutions Globally9.6.2026 16:20:00 EEST | Press release
Partnership combines Farasis Energy's advanced battery technology leadership with WLF Energy's integrated energy platform, AI-driven optimization capabilities, and global deployment strategy STUTTGART, GERMANY / ACCESS Newswire / June 9, 2026 / WLF Energy and Farasis Energy today announced the signing of a Strategic Partnership Agreement to jointly develop, industrialize, and commercialize next-generation battery technologies and energy storage products for global markets. The partnership establishes a long-term framework for collaboration across battery cell technology, battery systems, energy management software, artificial intelligence, and large-scale deployment of energy storage solutions. Together, both companies aim to accelerate the transition toward more affordable, resilient, and sustainable energy infrastructure worldwide. The agreement combines Farasis Energy's extensive experience in advanced battery technology development and manufacturing with WLF Energy's integrated tec
WLF Energy Launches as Europe's Fast, Clean, Bold New Vertically Integrated Clean Energy Champion; Built to Power a Continent9.6.2026 14:30:00 EEST | Press release
Energy platform goes public at The Battery Show Stuttgart, targeting sub-10ct/kWh clean energy for everyone in Europe - and laying the foundation for the continent's energy independence in the decade ahead. STUTTGART, DE / ACCESS Newswire / June 9, 2026 / WLF Energy GmbH today made its public debut at The Battery Show Europe in Stuttgart, unveiling its fully integrated clean-energy platform and long-term mission to deliver affordable, intelligent and sovereign energy infrastructure at global scale. The announcement was delivered by CEO and Chairman Sebastian Wolf, marking the company's first public appearance before a global audience of battery industry leaders, technology innovators and energy investors. The debut signals the arrival of a new kind of European energy company - one designed to integrate generation, storage, intelligence and energy trading into a single platform capable of making clean power the most affordable form of energy in Europe. Founded in 2026, WLF Energy is dev
U.S. Polo Assn. Returns to Downtown London as Official Apparel and Jersey Partner of Chestertons Polo in the Park9.6.2026 14:00:00 EEST | Press release
Over 30,000 Attendees Celebrate the Sport of Polo and ‘An Icon Born from the Game' WEST PALM BEACH, FL AND LONDON, UK / ACCESS Newswire / June 9, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), returned for the third consecutive year as the Official Apparel and Jersey Partner of Chestertons Polo in the Park, bringing together world-class competition, sport-inspired fashion, thrilling entertainment, and memorable lifestyle experiences for one of London's most anticipated summer sporting events. Held June 5-7, 2026, at Hurlingham Park in central London, the three-day festival welcomed more than 30,000 attendees for a celebration of the sport of polo in one of the world's most iconic urban settings. The Red Sea Global Team Riyadh and the Disney+ Team Rivals fighting for the ball at Chestertons Polo in the Park As the Official Apparel and Jersey Partner, U.S. Polo Assn. outfitted all teams throughout the tournament with custom-designed perfor
7 Days Left: LiberNovo Maxis, Big & Tall's Ultimate Seat9.6.2026 12:00:00 EEST | Press release
HONG KONG, HK / ACCESS Newswire / June 9, 2026 / Built from the ground up for larger frames, the Maxis series launches June 16 starting at €829, with super early bird savings up to 48% off MSRP. For Big & Tall buyers, the ergonomic chair search usually starts with the spec sheet. Most chairs in this segment are built on the standard ergonomic envelope and scaled up, not designed for a larger body in the first place. LiberNovo's Maxis series, launching June 16, is the brand's first line engineered from the start for that body. It ships in three configurations alongside two new additions to the LiberNovo Omni family. A larger geometry, by design Standard ergonomic chairs are sized for a body that runs around 5'9" and 170 pounds. Maxis is sized for the bodies that don't fit those numbers. Its 52 cm seat extends fully under the thigh, so the front edge won't cut off circulation by mid-afternoon. The frame is BIFMA-certified to 181 kg (399 lb), supported by a die-cast aluminum alloy base th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom